8-K: Milestone Pharmaceuticals Enters Amended Agreement for $77.8 Million Share Offering

Milestone Pharmaceuticals has entered into an amended agreement with Jefferies LLC to offer common shares up to an aggregate offering price of $77.8 million.

Summary

• Milestone Pharmaceuticals Inc. has entered into an Amended and Restated Open Market Sale Agreement with Jefferies LLC, as sales agent, on March 18, 2025.
• The agreement allows the company to offer common shares up to an aggregate offering price of $77.8 million, which includes approximately $2.8 million of sales previously made under the original agreement.
• Jefferies LLC will act as the sales agent and may sell the shares through an 'at the market' offering, including sales on the Nasdaq Global Select Market.
• The company will pay Jefferies a commission of 3.0% of the gross sales proceeds from the shares sold.
• The offering will terminate upon the sale of all shares or the termination of the agreement.
• The company intends to file a prospectus supplement related to the shelf registration statement on Form S-3.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard financial transaction (ATM offering) which provides the company with financial flexibility but also introduces potential dilution for existing shareholders. The terms are fairly standard for this type of agreement.

Positives

• The amended agreement provides Milestone Pharmaceuticals with access to additional capital through the sale of common shares.
• The 'at the market' offering allows for flexibility in selling shares based on market conditions.
• The company has the option, but not the obligation, to sell shares under the agreement.

Negatives

• The company will incur commission expenses of 3.0% on the gross sales proceeds.
• The sale of additional common shares may dilute existing shareholders' equity.
• The company is not obligated to sell any shares, so there is no guarantee of raising the full $77.8 million.

Risks

• Market conditions may not be favorable for selling shares at desired prices.
• The company's stock price could be negatively impacted by the announcement of the share offering.
• The company may not be able to fully utilize the $77.8 million offering if demand is insufficient.

Future Outlook

Milestone Pharmaceuticals intends to file a prospectus supplement in connection with the amended agreement, which will become effective upon filing.

Industry Context

At-the-market (ATM) offerings are a common method for publicly traded companies, particularly in the biotech and pharmaceutical sectors, to raise capital. They offer flexibility and can be less dilutive than traditional underwritten offerings if executed strategically. Other companies that have used ATM offerings include Agenus, Inc., and Veru Inc.

Comparison to Industry Standards

• The 3% commission is within the typical range for ATM offerings, which generally range from 1% to 4%.
• The legal expense reimbursement is also standard in these types of agreements.
• Comparable companies such as Agenus Inc. and Veru Inc. have utilized ATM offerings with similar commission structures and legal expense reimbursements.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the company sells a significant number of shares.
• The company's financial position may be strengthened by the additional capital raised through the offering.
• Employees may benefit from the company's increased financial stability and ability to invest in growth initiatives.

Next Steps

• Milestone Pharmaceuticals intends to file a prospectus supplement with the SEC.
• Jefferies LLC will begin offering the common shares under the terms of the amended agreement, subject to market conditions and the company's instructions.

Key Dates